EstroG-100 Reduces Menopausal Symptoms

ANAHEIM, Calif.EstroG-100, an herbal product containing a mixture of standardized extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas from Helios CORP and Sunbio Corp. significantly improved the menopausal symptoms of pre-, peri- and post-menopausal women without weight gain or any serious side effects in a new study (Phytother Res. 2011 Sep 2. DOI: 10.1002/ptr.3597).

This randomized double blind, placebo-controlled trial was performed for 12 weeks with 64 pre-, peri- and postmenopausal white Hispanic, white non-Hispanic and African American women who were randomly allocated to either the EstroG-100 group (n=31) or the placebo group (n=33). Primary end-points were the mean change in scores of the Kupperman menopause index (KMI) that evaluates 11 symptoms and the mean change in scores of vaginal dryness.

The mean KMI score was significantly reduced in the EstroG-100 group from 29.5±7.4 at baseline to 11.3±5.8 (P<0.01) compared with change of the placebo group (29.2±6.6 at baseline vs. 23.7±7.7 at week 12). Other menopausal symptoms such as insomnia, nervousness, melancholia, vertigo, fatigue and rheumatic pain were significantly improved in the EstroG-100 group in comparison with the placebo group (P<0.05). Statistically significant improvements also occurred in vaginal dryness in the EstroG-100 group compared to the placebo group (P<0.05).

As an ingredient, EstroG-100 has been in the U.S. market for the past four years. EstroG-100 received a Health Canada Product License Number in 2011 that confirms 10 end point claims based on its review and evaluation of the Phase II human clinical study

Utilizing the Kupperman Index study model for menopause in a 2010 Phase II human clinical study, EstroG-100 showed significant improvement in nine of 11 end points, along with an additional significant improvement in vaginal dryness. Also, hGH levels increased by 100 percent, which can be directly attributed to improvements in energy level, skin moisture and tone.